MetaCap

Celldex Therapeutics Inc. (CLDX)

NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

27.42-0.54 (-1.93%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CLDX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.29
52-week range
22.33 – 45.14
Day range
26.64 – 28.43
Volume / Avg
1.72M / 1.33M
Beta
—

52-week range

$22.33$45.14

CLDX stock today

On Nov 20, CLDX ended the session at $27.42, shedding $0.54 (1.93%), versus the S&P 500's 3.70% decline. Shares are 39.3% below their 52-week high of $45.14, set on Aug 12, 2026 and 22.8% above the 52-week low of $22.33, in the middle of the past year's range. CLDX is up 1.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 5.8%.

Celldex Therapeutics has posted a net loss over the last twelve months (EPS of -$4.29), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Celldex Therapeutics

Company profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Anthony S. Marucci M.B.A.
Headquarters
Hampton, NJ
Employees
198

Financial highlights

Full financials

In fiscal 2025, Celldex Therapeutics generated $1.5 million in revenue, down 78.0% from fiscal 2024, its first annual decline since 2022. Celldex Therapeutics reported a net loss of $258.8 million, compared with a loss of $157.9 million a year earlier. Gross margin was 87.1% (down from 97.2%) and operating margin -18599.8%.

Celldex Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.54M$7.02M$6.88M$2.36M$4.65M
Growth-77.99%+1.99%+192.02%-49.32%-37.30%
Net income$-258.76M$-157.86M$-141.43M$-112.33M$-70.51M
EPS (diluted)$-3.90$-2.45$-2.92$-2.40$-1.64

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$64.00+133.41%

  • Strong buy 2
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $29.00High $100.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.96 vs $-1.02
Surprise
+5.88%

CLDX news

All CLDX news

Celldex Therapeutics peers

Health Care sector
CLDX peer companies
CompanyPrice% ChgMarket capCompare
NEOGNeogen Corporation10.55-2.77%$2.30Bvs CLDX
NTLAIntellia Therapeutics Inc.10.00+5.04%$1.40Bvs CLDX
QUITAchieve Life Sciences Inc.5.56-5.28%$573.25Mvs CLDX
QDELQuidelOrtho Corporation8.32-6.73%$570.86Mvs CLDX
MYGNMyriad Genetics Inc.5.46-1.44%$523.74Mvs CLDX
TKNOAlpha Teknova Inc.7.63-2.30%$479.95Mvs CLDX
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs CLDX
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs CLDX

Indexes, lists and sector

Celldex Therapeutics stock FAQ

What is Celldex Therapeutics's stock price today?

CLDX last traded at $27.42 as of Nov 20, 4:00 PM EST, down 1.93% on the day. Prices are delayed at least 15 minutes.

Does Celldex Therapeutics pay a dividend?

No. Celldex Therapeutics does not currently pay a regular cash dividend.

Who is Celldex Therapeutics's CEO?

Mr. Anthony S. Marucci M.B.A. is the chief executive officer of Celldex Therapeutics Inc., which has about 198 employees.

Has CLDX ever split its stock?

Yes. The most recent CLDX stock split was a 1-for-15 split on Feb 11, 2019, one of 2 splits on record.

What is the CLDX 52-week high?

The 52-week high for CLDX is $45.14 and the 52-week low is $22.33. The stock is currently 39.3% below its high.

Compare CLDX